Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma

NCT03854474 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03854474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03854474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 18, 2019
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced urothelial carcinoma, metastatic urothelial carcinoma, stage iii bladder cancer ajcc v8, stage iv bladder cancer ajcc v8